Literature DB >> 11408513

Clinical trial designs for cytostatic agents.

M J Ratain, W M Stadler.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11408513     DOI： 10.1200/JCO.2001.19.12.3154

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  A comparison of phase II study strategies.

Authors:  Sally Hunsberger; Yingdong Zhao; Richard Simon
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 2.  Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Authors:  Tatiana Vidaurre; Julia Wilkerson; Richard Simon; Susan E Bates; Tito Fojo
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

3.  Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

Authors:  John R Goffin; Greg R Pond
Journal:  BMC Med Res Methodol       Date:  2011-12-12       Impact factor: 4.615

4.  Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.

Authors:  Akihiro Hirakawa; Kan Yonemori; Fumie Kinoshita; Yumiko Kobayashi; Hitomi S Okuma; Asuka Kawachi; Kenji Tamura; Yasuhiro Fujiwara; Larry Rubinstein; Pamela Jo Harris; Naoko Takebe
Journal:  Cancer Sci       Date:  2017-12-08       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.